MILAN--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm ManagementTM. Under the terms of the transaction, Sorin also acquired the exclusive right to distribute the remede® System for the next five years in selected countries in Europe and an exclusive option to acquire Respicardia in the future. Respicardia is based in Minneapolis, Minnesota (USA).
Respicardia has developed the first fully implantable device for the treatment of central sleep apnea (CSA). The remede® System is a pacemaker-like device that delivers electrical pulses via an implantable transvenous lead to the phrenic nerve which restores a more natural, less disrupted breathing pattern. The remede® System received CE Mark approval in 2010 and is currently being evaluated in an FDA approved randomized, controlled IDE pivotal trial.
Help employers find you! Check out all the jobs and post your resume.
